The APAC doxorubicin market is expected to grow from US$ 257.33 million in 2022 to US$ 386.82 million by 2028; it is estimated to grow at a CAGR of 7.0% from 2022 to 2028.
Cancer treatment has yielded better results, but access to medicines has become a problem across the region, especially in low- and middle-income countries. However, replacing it with a generic drug can save significantly. The doxorubicin market is characterized by the presence of large and small companies. Players are taking up product launches, regional expansions, and technological advancements to increase their market share. Continuous innovations and technological advancements result in safer and more effective doxorubicin drugs, increasing acceptance among patients and medical societies. Several developments have taken place in the recent years. For instance, in September 2020, Zydus Cadila received final approval for the commercialization of its generic doxorubicin hydrochloride liposome injection. Further, in September 2018, Hikma Pharmaceuticals PLC launched Adriamycin (DOXOrubicin HCl) for injection as a part of multi-agent adjuvant chemotherapy for treatment of women with axillary lymph node association following resection of primary breast cancer. Thus, approval of generic substitution for frequently used chemotherapy drugs, such as doxorubicin, in treating common cancers has a vast potential to increase significant cost savings and rising access to cancer treatments in several countries across the region.
With the new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the APAC doxorubicin market. The APAC doxorubicin market is expected to grow at a good CAGR during the forecast period.
APAC Doxorubicin Market Revenue and Forecast to 2028 (US$ Million)
APAC Doxorubicin Market Segmentation
The APAC doxorubicin market is segmented based on drug formulation, application, distribution channel, and country. Based on drug formulation, the APAC doxorubicin market is bifurcated into lyophilized powder and doxorubicin injection. The lyophilized powder segment dominated the market in 2022. Based on application, the APAC doxorubicin market is segmented into breast cancer, kidney cancer, liver cancer, sarcoma, ovarian cancer, lung cancer, leukemia, multiple myeloma, and others. The breast cancer segment dominated the market in 2022. Based on distribution channel, the APAC doxorubicin market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The hospital pharmacy segment dominated the market in 2022. Based on country, the APAC doxorubicin market has been categorized into China, India, Japan, South Korea, Australia, and Rest of APAC. Our regional analysis states that China dominated the market in 2022.
Accord Healthcare; Baxter International Inc.; Cipla Inc.; Dr. Reddy's Laboratories; Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.); Meiji Holdings Co., Ltd.; Novartis AG; Pfizer Inc.; Sun Pharmaceutical Industries Ltd; and Zydus Cadila are among the leading companies in the APAC doxorubicin market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 257.33 Million |
| Market Size by 2028 | US$ 386.82 Million |
| CAGR (2022 - 2028) | 7.0% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Drug Formulation
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Doxorubicin Market is valued at US$ 257.33 Million in 2022, it is projected to reach US$ 386.82 Million by 2028.
As per our report Asia Pacific Doxorubicin Market, the market size is valued at US$ 257.33 Million in 2022, projecting it to reach US$ 386.82 Million by 2028. This translates to a CAGR of approximately 7.0% during the forecast period.
The Asia Pacific Doxorubicin Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Doxorubicin Market report:
The Asia Pacific Doxorubicin Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Doxorubicin Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Doxorubicin Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Doxorubicin Market
